Publicaciones en las que colabora con Manuel Barreiro de Acosta (10)

2022

  1. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  3. Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 668-676

  4. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  5. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 11, pp. 1846-1851

  2. Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42

2020

  1. Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis

    Clinical and translational gastroenterology, Vol. 11, Núm. 8, pp. e00218

2019

  1. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

    Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428

  2. Increased risk of thiopurine-related adverse events in elderly patients with IBD

    Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 7, pp. 780-788